View Older Stories View More Recent Stories

Nov 26, 2024 08:00AM New Data from a Long-Term Follow-up Study to the OLYMPUS Trial Show Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO®
Nov 6, 2024 08:00AM UroGen Pharma Reports 2024 Third Quarter Financial Results and Business Highlights, Including the Potential Launch of UGN-102 in 2025
Nov 5, 2024 08:00AM UroGen Pharma to Present at the Guggenheim Securities Healthcare Innovation Conference
Oct 30, 2024 08:00AM UroGen Pharma to Report Third Quarter Financial Results on Wednesday, November 6, 2024
Oct 15, 2024 04:31PM UroGen Pharma (URGN) Announces FDA Acceptance of its NDA for UGN-102
Oct 15, 2024 04:30PM UroGen Announces FDA Acceptance of its New Drug Application for UGN-102
Oct 2, 2024 08:00AM First Patient Dosed in Phase 3 Clinical Trial of UGN-103, a Next Generation Mitomycin-Based Formulation in Development for the Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Canc
Sep 16, 2024 08:02AM UroGen Pharma (URGN) Receives New U.S. Patent Allowance for Next-Generation Mitomycin-Based Products Expected to Provide Protection Until December 2041
Sep 16, 2024 08:00AM UroGen Receives New U.S. Patent Allowance for Next-Generation Mitomycin-Based Products Expected to Provide Protection Until December 2041
Sep 5, 2024 08:00AM UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 29, 2024 08:00AM UroGen Pharma to Present at Upcoming Investor Conferences
Aug 14, 2024 08:00AM UroGen Pharma (URGN) Submits Completed UGN-102 NDA Seeking Approval as the First FDA-Approved Treatment for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
Aug 14, 2024 08:00AM UroGen Submits Completed UGN-102 NDA Seeking Approval as the First FDA-Approved Treatment for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
Aug 13, 2024 08:00AM UroGen Pharma Ahead of Schedule to Complete UGN-102 NDA Submission and Reports 2024 Second Quarter Financial Results and Business Highlights
Jun 13, 2024 10:45AM UroGen (URGN) Announces 82.3% Duration of Response at 12 Months in ENVISION Trial Investigating UGN-102 as Potentially the First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC
Jun 13, 2024 10:45AM UroGen Announces Unprecedented 82.3% Duration of Response at 12 Months in the ENVISION Trial Investigating UGN-102 as Potentially the First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC
Jun 7, 2024 08:00AM UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jun 5, 2024 08:00AM UroGen Pharma to Present at the 45th Annual Goldman Sachs Global Healthcare Conference
Jun 3, 2024 08:02AM UroGen Pharma (URGN) Appoints David Lin as Chief Commercial Officer
Jun 3, 2024 08:00AM UroGen Pharma Appoints David Lin as New Chief Commercial Officer
May 22, 2024 08:00AM UroGen Pharma to Present at the TD Cowen 5th Annual Oncology Innovation Summit
May 13, 2024 08:00AM UroGen Pharma Announces Date for ENVISION Data, New Long-Term Jelmyto Durability Data, and Reports 2024 First Quarter Financial Results and Business Highlights
May 7, 2024 08:00AM UroGen Pharma to Participate at Upcoming Investor Conferences
May 5, 2024 12:20PM New Real-World Retrospective Analysis Presented at AUA 2024 Reports 86% Recurrence-Free Survival (RFS) at 24 Months with JELMYTO® Across All Studied Patient and Disease Characteristics in Cohort of R
May 4, 2024 03:20PM UroGen Announces Results from ATLAS Showing Robust UGN-102 Durability of Response in New and Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer at AUA 2024
May 4, 2024 11:50AM New Real-World Study on Retrograde Instillation of JELMYTO® for Treatment of Low-Grade Upper Tract Urothelial Cancer Reports Similar Complete Response Rate and Lower Stricture Rate Compared to OLYMPU
May 3, 2024 08:00AM UroGen Pharma to Report 2024 First Quarter Financial Results on Monday, May 13, 2024
Apr 17, 2024 12:02PM UroGen Announces New Data Presentations at the American Urological Association 2024 Annual Meeting Highlighting Clinical Benefits of Our Portfolio for Urothelial Cancers
Apr 15, 2024 08:01AM UroGen Pharma (URGN) Announces FDA Acceptance of Investigational New Drug Application for UGN-103
Apr 15, 2024 08:00AM UroGen Announces FDA Acceptance of Investigational New Drug Application for UGN-103, a Next Generation Mitomycin-Based Formulation for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
Apr 3, 2024 08:03AM UroGen Pharma (URGN) Files Patent Infringement Action Against Teva Pharmaceuticals (TEVA)
Apr 3, 2024 08:00AM UroGen Pharma Files Patent Infringement Action Against Teva Pharmaceuticals
Mar 14, 2024 08:00AM UroGen Pharma Delivers Double Digit JELMYTO® Growth and Prepares for the Next Phase of the Company with on Track Rolling Submission of UGN-102
Mar 8, 2024 08:00AM UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mar 4, 2024 08:00AM UroGen Pharma to Report Fourth Quarter and Full-Year 2023 Financial Results on Thursday, March 14, 2024
Feb 26, 2024 08:00AM UroGen Pharma to Present at TD Cowen 44th Annual Health Care Conference
Feb 1, 2024 08:00AM UroGen Pharma to Participate at Upcoming Investor Conferences
Jan 24, 2024 08:00AM UroGen Pharma (URGN) Initiates Submission of a Rolling NDA to the FDA for UGN-102
Jan 24, 2024 08:00AM UroGen Initiates Submission of a Rolling NDA to the FDA for UGN-102
Jan 17, 2024 08:00AM UroGen Secures Exclusive License from medac GmbH to Develop a Next-Generation Novel Mitomycin-Based Formulation for Urothelial Cancers
Jan 11, 2024 08:00AM UroGen Pharma to Participate in the B. Riley Healthcare Conference
Dec 8, 2023 04:00PM UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 14, 2023 08:00AM UroGen Pharma Reports Third Quarter 2023 Financial Results
Nov 13, 2023 08:00AM UroGen will Present Scientific Advances in Bladder Cancer at the Annual Meeting of the Society of Urologic Oncology
Nov 7, 2023 08:00AM UroGen Pharma to Report Third Quarter 2023 Financial Results on Tuesday, November 14, 2023
Oct 3, 2023 08:01AM UroGen Pharma (URGN) Announces Rolling NDA Submission for UGN-102 to Begin January 2024
Oct 3, 2023 08:00AM Following Pre-NDA Meeting with the FDA, UroGen Announces Rolling NDA Submission for UGN-102 to Begin January 2024
Sep 11, 2023 07:00AM Eledon Pharmaceuticals Appoints Industry Veteran James Robinson to its Board of Directors
Sep 8, 2023 08:00AM UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 31, 2023 08:00AM UroGen Pharma to Present at Upcoming Investor Conferences
View More Recent Stories View Older Stories